Article Correctness Is Author's Responsibility: FDA Approves New Nuplazid Formulation, Dosage Strength

The article below may contain offensive and/or incorrect content.

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson disease psychosis.